Pfizer took its next steps Tuesday in its attempted resurrection in the obesity market.
The pharma firm said that an experimental weight loss drug, recently picked up through the company’s contested acquisition of the biotech Metsera, hit its marks in a mid-stage study, demonstrating the potential to be a once-a-month treatment.
Investors, however, will be parsing the data to assess how they compare to outcomes demonstrated by other drugs in the increasingly competitive obesity market. Pfizer’s share price was down some 4% in pre-market trading as the company also reported 2025 earnings.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
<
Leave a Reply